XML 39 R30.htm IDEA: XBRL DOCUMENT v3.25.3
Surface Acquisition (Tables)
12 Months Ended
Dec. 31, 2024
Surface Acquisition  
Schedule of total consideration paid

(in thousands, except share and per share amounts)

As of Acquisition Date

Coherus common stock issued

11,971,460

Coherus common stock share price

$

4.89

Fair value of components of purchase price consideration at closing:

Equity of combined company owned by Surface equity holders

$

58,540

Contingent CVR liability

5,290

Equity of combined company owned by Surface former employees (1)

766

Fair value of total purchase consideration

$

64,596

(1)Represents 161,100 shares of Coherus common stock, net of shares withheld for taxes, issued to Surface’s former employees on the Acquisition Date.
Schedule of purchase price allocation to the estimated fair value of the net assets acquired

(in thousands)

Amounts Recognized at Acquisition Date

Assets Acquired

Cash and cash equivalents

$

6,997

Investments in marketable securities

21,791

Prepaids and other assets

5,260

In-process research and development

26,239

Out-licenses

13,530

Total assets

$

73,817

Liabilities Assumed

Accrued and other current liabilities

$

7,722

Deferred tax liability

1,499

Total liabilities

9,221

Total net assets acquired

$

64,596

Schedule of amounts allocated to identifiable intangible assets

(in thousands)

Useful lives

    

Fair Value at Acquisition Date

In-process research and development - casdozokitug

n/a

$

25,899

In-process research and development - CHS-114

n/a

340

Out-license - GSK

15 years

2,506

Out-license - Novartis Institutes

15 years

11,024

Total identifiable intangible assets

$

39,769

Schedule of unaudited pro forma summary of operations

(in thousands)

Year Ended December 31, 2023

Total revenues

$

257,244

Net loss

$

(284,575)